共 57 条
Nitrosyl/Diphenylphosphine/Amino Acid-Ruthenium Complexes as Inhibitors of MDA-MB-231 Breast Cancer Cells
被引:5
作者:
Barbosa, Marilia I. F.
[1
]
Correa, Rodrigo S.
[2
]
Guedes, Adriana P. M.
[3
]
Graca, Alex M.
[3
]
Andrade, Francyelli M.
[4
]
Leite, Celisnolia M.
[3
]
Silveira-Lacerda, Elisangela P.
[4
]
Ellena, Javier
[5
]
Reis, Henrique V.
[1
]
Doriguetto, Antonio C.
[1
]
Batista, Alzir A.
[3
]
机构:
[1] Univ Fed Alfenas, Inst Quim, BR-37130000 Alfenas, MG, Brazil
[2] Univ Fed Ouro Preto, Dept Quim, BR-35400000 Ouro Preto, MG, Brazil
[3] Univ Fed Sao Carlos, Dept Quim, BR-13565905 Sao Carlos, SP, Brazil
[4] Univ Fed Goias, Lab Genet Mol & Citogenet, Inst Ciencias Biol, BR-74690900 Goiania, GO, Brazil
[5] Univ Sao Paulo, Inst Fis Sao Carlos, BR-13560970 Sao Carlos, SP, Brazil
来源:
基金:
巴西圣保罗研究基金会;
关键词:
ruthenium;
diphenylphosphine;
amino acids;
nitric oxide;
breast cancer cells;
CYTOTOXIC ACTIVITIES;
STRUCTURAL FEATURES;
NITROSYL COMPLEXES;
DNA;
APOPTOSIS;
HOECHST-33258;
CRYSTAL;
LIGANDS;
ALBUMIN;
BINDING;
D O I:
10.3390/inorganics11070270
中图分类号:
O61 [无机化学];
学科分类号:
070301 ;
081704 ;
摘要:
Herein, we report on the synthesis and characterization of ruthenium compounds with the general formula [RuCl(AA-H)(NO)(dppb]PF6, where AA = glycine (1), L-alanine (2), L-phenylalanine (3) and L-valine (4), and dppb = 1,4-bis(diphenylphosphine)butane. The complexes were characterized using elemental analysis, UV/Vis and infrared spectroscopies, H-1, C-13, P-31 NMR techniques, and cyclic voltammetry. Furthermore, the structures of the compounds (1) and (3) were determined using single-crystal X-ray diffraction. In vitro evaluation of the Ru(II)/nitrosyl/amino acid complexes revealed their cytotoxic activities against triple-negative MDA-MB-231 breast cancer cells, and against the non-tumor murine fibroblast cells. All the compounds decreased the percentage of viable cells, inducing cell death by apoptosis. Additionally, the Ru(II) complexes inhibited the migration of MDA-MB-231 cells at concentrations lower than 35 & mu;M, after 48 h of exposure. Thus, these complexes may be promising agents for the treatment of triple-negative MDA-MB-231 breast cancer.
引用
收藏
页数:22
相关论文